User:HealthLeaders Trends/sandbox

Prof. Bandar A. Alknawy (Arabic: بندر بن عبدالمحسن القناوي ) has been Chief Executive Officer of Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdul-Aziz University for Health Sciences, Saudi Arabia since 2009. He served as General Supervisor of the Royal Clinics of the late King Abdullah Bin Abdul-Aziz Al Saud, Custodian of the Two Holy Mosques, between 2009 and 2015.

Prof. Alknawy is a known transformational leader in the Kingdom. He has led major projects in MNGHA. He established specialized hospitals, state-of-the-art facilities, and led many distinguished programs and conferences in the health fields.

Early life
Prof. Al Knawy was born in Makkah, Saudi Arabia. He completed his undergraduate degree at King Abdulaziz University in Jeddah and specialized in gastroenterology and hepatology at the Dalhousie University in Canada.

Education

 * Clinical Fellowship, Gastroenterology Fellowship Program. Dalhousie University.  (1991- 1992)
 * Residency, Internal Medicine Residency Program. Dalhousie University. (1987 – 1990)
 * Bachelor of Medicine, Bachelor of Surgery (M.B.B.S). King Abdul-Aziz University. (1979 – 1985)

Professional Career

 * Chief Executive Officer, Ministry of National Guard Health Affairs, since 2009
 * President, King Saud bin Abdul-Aziz University for Health Sciences, since 2009
 * General Supervisor of the Royal Clinics of the late King Abdullah Bin Abdul-Aziz Al Saud. (2009 – 2015)
 * General Supervisor – Dialysis Care Project, King Abdullah Bin Abdulaziz Al Saud International Foundation for Charity, and Humanitarian Works, since 2014

Achievements
Prof. Al Knawy is a strong advocate of patient safety and quality of care and oversaw the launch of several high-impact initiatives including

His Achievements in MNGHA
 * The Annual National Patient Safety Forum
 * The Saudi Medication Safety Program
 * Spearheaded the Riyadh Global Digital Health Summit. The summit envisioned a global health system connectivity in preparedness and response to COVID-19 Pandemics. The event has been described as one of the largest virtual health conferences of the year and certainly largest one on public health combined with digital health.
 * Spearheaded the Riyadh Global Medical Biotechnology Summit, which was under the auspices of HRH Crown Prince Mohammed bin Salman bin Abdul-Aziz
 * 1) During his term as CEO, Prof. Al Knawy has led MNGHA’s transformation from a national provider of primary and secondary healthcare to a pioneering regional and global academic health system. This has involved  o  The addition of specialized hospitals,  o  An international research center,  o   and the University for Health Sciences.  o   MNGHA, a world first, in recognition of it's commitment to improving the quality of patient care, ensuring safety, continually working to reduce risks, and achieving the highest           standards of medical care
 * 2) An international pioneering program for the separation of conjoined twins to deliver some of the best outcomes globally
 * 3) Managing a major crisis and successfully transforming emergency care (Pdf link as a reference)  In 2015, MNGHA was faced with the extremely tough challenge of a MERS-COV outbreak, which posed a significant risk to patients, staff, and overall healthcare delivery. Dr Al Knawy quickly and effectively minimized the effects of the outbreak on patients and staff. He transformed the crises into an opportunity to lead one of the most radical and ambitious programs of its kind; using the “Right Care, Right now” and “Zero Tolerance to Delay” principles, Dr Al Knawy created the momentum to transform the emergency care and infection control practices. MNGHA is now recognized as the place to go to learn how to achieve excellent outcomes in a very short space of time.
 * 4) Developing and successfully implementing a large-scale electronic health record (EHR) system  MNGHA developed and implemented a highly advanced EHR system to integrate records across primary, secondary, and tertiary care in a single platform across all medical facilities in Saudi Arabia. This provided a tool for safer and more efficient patient care and facilitated a new research direction. It is MNGHA’s ambition, under Dr Al Knawy’s leadership, to become truly a data-driven healthcare organization and world leader in this area
 * 5) Health provision expansion  Under DAl Knawy’s leadership, MNGHA has undergone unprecedented and successful expansion to 3,500 beds, 106,000 annual admissions, and 2,375,000 active medical files across five medical cities and 71 primary care centers.
 * 6) Under his leadership, MNGHA developed several programs with nationwide impact that are based in and led by MNGHA, including  o   The National Family Safety Program, to prevent child maltreatment and domestic violence in the Kingdom  o   The National & Gulf Center for Evidence-Based Health Practice (NGCEBHP), officially recognized by the GCC ministers of Health as an evidence-based health practice referral center for Saudi Arabia and the wider Gulf region

Publications
Prof. Al Knawy is a clinical expert in hepatology, authoring and editing four books in the health field. In efforts to disseminate expertise and experience in healthcare management, he edited “Leading Reliable Healthcare”, a book that for the first-time complied perspectives from global health system leaders to deliver a valuable addition to the healthcare management literature.

Books

 * Leading Reliable Healthcare, Bandar Al Knawy, editor. Taylor & Francis; 2017 Dec 15, ISBN 9781138197510.
 * Health Care-Associated Transmission of Hepatitis B and C Viruses, An Issue of Clinics in Liver Disease, ISBN 9781437719154
 * Hepatocellular Carcinoma: A Practical Approach, Editors: Bandar Al Knawy, K. Rajender Reddy & Luigi Bolondi, Informa Healthcare, September 2009, ISBN 978-0415480802
 * Hepatology: A Practical Approach. Editors: Bandar Al Knawy, Mitchell L. Shiffman & Russell H. Wiesner, Elsevier, December 2004, ISBN 978-0444513441

Journals

 * 1) Chua A. Al Knawy B. et al. How the lessons of previous epidemics helped successful countries fight covid-19 BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n486
 * 2) Al Knawy B (2021) Global Data and Digital Public Health Leadership for Current and Future Pandemic Responses. Front. Digit. Health 3:632568. doi:10.3389/fdgth.2021.632568
 * 3) Al Knawy B, Kozlakidis Z. The ‘Quaranta Giorni’ Leadership Test: Time to Transform Healthcare. BMJ Leader 2020. (forthcoming). http://dx.doi.org/10.1136/leader-2020-000276
 * 4) Al Knawy B, Adil M, Crooks G, Rhee K, Bates D, Jokhdar H, Klag M, Lee U, Mokdad A, Schaper L, Al Hazme R, Al Khathaami A, Abduljawad J. The Riyadh Declaration: The Role of Digital Health in Fighting Current and Future Pandemics Invited Comment. The Lancet. 2020 September 22 https://doi.org/10.1016/S0140-6736(20)31978-4.
 * 5) AlKnawy B Leadership in times of crisis BMJ Leader 2019;3:1-5.
 * 6) Al Knawy BA, Al-Kadri HMF, Elbarbary M, et al Perceptions of postoutbreak management by management and healthcare workers of a Middle East respiratory syndrome outbreak in a tertiary care hospital: a qualitative study BMJ Open 2019;9:e017476. doi: 10.1136/bmjopen-2017-017476
 * 7) Aziz MA, Yousef Z, Saleh AM, Mohammad S, Al Knawy B. Towards personalized medicine of colorectal cancer. Critical Reviews in Oncology/Hematology. 2017 Oct 1;118:70-8.
 * 8) Al-Qahtani S, Al-Dorzi HM, Tamim HM, Hussain S, Fong L, Taher S, Al Knawy BA, Arabi Y. Impact of an intensivist-led multidisciplinary extended rapid response team on hospital-wide cardiopulmonary arrests and mortality. Critical Care Medicine. 2013 Feb 1;41(2):506-17.
 * 9) Khan A, Al Balwi MA, Tanaka Y, Hajeer A, Sanai FM, Al Abdulkarim I, Al Ayyar L, Badri M, Saudi D, Tamimi W, Mizokami M, Al Knawy BA. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. International Journal of Cancer. 2013 Dec 15;133(12):2864-71.
 * 10) Cherfan AJ, Tamim HM, AlJumah A, Rishu AH, Al-Abdulkareem A, Al Knawy BA, Hajeer A, Tamimi W, Brits R, Arabi YM. Etomidate and mortality in cirrhotic patients with septic shock. BMC Clinical Pharmacology. 2011 Dec;11(1):22.
 * 11) Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Al Knawy BA, Hajeer AH, Tamimi W, Cherfan A. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. Canadian Medical Association Journal. 2010 Dec 14;182(18):1971-7.
 * 12) Memish ZA, Al Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. International Journal of Infectious Diseases. 2010 Feb 1;14(2):e115-20.
 * 13) Al-Jumah M, Abolfotouh MA, Alabdulkareem IB, Balkhy HH, Al-Jeraisy MI, Al-Swaid AF, Al-Musaaed EM, Al Knawy BA. Public attitude towards biomedical research at outpatient clinics of King Abdulaziz Medical City, Riyadh, Saudi Arabia. Eastern Mediterranean Health Journal. 2011 Jun 1;17(6):536.
 * 14) Hajeer AH, Al Knawy BA, Alhaj-Hussein BT, Al-Rubiaan SD. Hepatitis B virus: A study of genotypes in an infected Saudi cohort. British Journal of Biomedical Science. 2007 Apr 1;64(2):93.
 * 15) Al Knawy BA. Is hepatocellular carcinoma preventable?. Saudi Medical Journal. 2007;28(6):829-30.
 * 16) Al Knawy BA, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver International. 2007 Nov 1;27(9):1166-73.
 * 17) Almuneef MA, Memish ZA, Balkhy HH, Qahtani M, Alotaibi B, Hajeer A, Qasim L, Al Knawy BA. Epidemiologic shift in the prevalence of Hepatitis A virus in Saudi Arabia: a case for routine Hepatitis A vaccination. Vaccine. 2006 Jul 7;24(27-28):5599-603.
 * 18) Arabi Y, Al Knawy BA, Barkun AN, Bardou M. Pro/con debate: Octreotide has an important role in the treatment of gastrointestinal bleeding of unknown origin?. Critical Care. 2006 Aug;10(4):218.
 * 19) Hajeer AH, Memish ZA, Al Knawy BA. Laboratory diagnosis of Hepatitis C virus infection. A change to common practice. Saudi Medical Journal. 2004;25(7):827-9.
 * 20) Qasim L, Abed E, Memish Z, AlBasheer A, Aldraihim A, Al Knawy BA, Hajeer AH. Pattern of viral hepatitis infection in a selected population from Saudi Arabia. Military Medicine. 2003 Jul 1;168(7):565-8.
 * 21) Al Knawy BA, Okamoto H, El-Mekki AA, Khalafalla ME, Al Wabel A, Qazi F, Khan A, Shatoor A. Distribution of hepatitis C genotype and co-infection rate with hepatitis G in Saudi Arabia. Hepatology Research. 2002 Oct 1;24(2):95-8.
 * 22) Al Knawy BA. Ribavirin. Saudi Journal of Gastroenterology. 2001 Jan 1;7(1):42.
 * 23) Al-Moamary MS, Gorka T, Al-Traif IH, Al-Jahdali HH, Al-Shimemeri AA, Al Knawy BA, Abdulkareeem AA. Pulmonary changes in liver transplant candidates with hepatitis C cirrhosis. Saudi Medical Journal. 2001 Dec;22(12):1069-72.
 * 24) Al-Humayed S, Mayet I, Al-Juhani M, Al Knawy BA, George K, Sbeih F. Treatment of chronic hepatitis C genotype IV with interferon±ribavirin combination in Saudi Arabia: a multicentre study. Journal of Viral Hepatitis. 2000;7:287ą291.
 * 25) Harakati MS, Abualkhair OA, Al Knawy BA. Hepatitis C Virus infection in Saudi Arab patients with B-cell non-Hodgkin's lymphoma. Saudi Medical Journal. 2000;21(8):755-8.
 * 26) Williams CN, Al Knawy BA, Blanchard W. Bioavailability of four ursodeoxycholic acid preparations. Alimentary Pharmacology and Therapeutics. 2000 Sep 1;14(9):1133-40.
 * 27) Al Knawy BA, El-Bagir M, Ahmed K, Elmekki AA, Mirdad S. Sero-epidemiology of Helicobacter pylori and Relation to Socioeconomic Factors in Saudi Arabia. A Population Study. Gastroenterology International. 1999;12(3):108-12.
 * 28) Al Knawy BA. Gastroenterology in the kingdom of Saudi Arabia. International Journal Of Gastroenterology. 1999;4:5-8.
 * 29) Al Knawy BA, Morad N, Jamal A, Mirdad S, Fotouh MA, Ahmed ME, Saydain G, Seidi O, Shatoor A. Helicobacter pylori and intestinal metaplasia with its subtypes in the gastric antrum in a Saudi population. Scandinavian Journal of Gastroenterology. 1999 Jan 1;34(6):562-5.
 * 30) Al Traif I, Fachartz FS, Al Jumah A, Al Johani M, Al Omair A, Al Bakr F, Al Knawy BA, El Hafi A, Khan MH. Randomized trial of ligation versus combined ligation and sclerotherapy for bleeding esophageal varices. Gastrointestinal Endoscopy. 1999 Jul 1;50(1):1-6.
 * 31) Al Knawy BA, Bilal NE, Mohammad El Bagir KA, Al-Wabel AA, Foli AK, Al-Humaidi MA, Shatoor AS, Mirdad S, Abolfotouh M. Metronidazole-resistant Helicobacter pylori strains among Saudi patients with dyspepsia. Saudi Medical Journal. 1997 May 1;18(3):261.
 * 32) Al Knawy BA, El-Mekki AA, Yarbough PO. The role of hepatitis E virus infection among patients with acute viral hepatitis in southern Saudi Arabia. Annals of Saudi medicine. 1997 Jan;17(1):32-4.
 * 33) Al Knawy BA. Etiology of ascites and the diagnostic value of serum-ascites albumin gradient in non-alcohol liver disease. Annals of Saudi Medicine. 1997 Jan;17(1):26-8.
 * 34) Ahmed ME, Al Knawy BA, Al-Wabel AH, Malik GM, Foli AK. Acute upper gastrointestinal bleeding in southern Saudi Arabia. Journal of the Royal College of Physicians of London. 1997;31(1):62-4.
 * 35) Ahmed M, Al Knawy BA, Al-Wabel AH, Foli AK. Duodenal ulcer and Helicobacter pylori infection at high altitude: experience from southern Saudi Arabia. Canadian Journal of Gastroenterology and Hepatology. 1997;11(4):313-6.
 * 36) Al Knawy BA, Morad NA, Jamal A, Hamdi J, Mirdad S. Non-neoplastic changes in gastric antrum: are they different in distally located intestinal and diffuse-type gastric adenocarcinoma?. European Journal of Cancer Prevention. 1997 Apr;6(2):167-70.
 * 37) Okamoto H, Kobata S, Tokita H, Inoue T, Woodfield GD, Holland PV, Al Knawy BA, Uzunalimoglu O, Miyakawa Y, Mayumi M. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. Journal of virological methods. 1996 Mar 1;57(1):31-45.
 * 38) Admed ME, Morad N, Al Knawy BA. Identifying helicobacter pylori: is H and E staining enough?. Saudi Medical Journal. 1997 May 1;18(3):264-6.
 * 39) Al Knawy BA, El-Mekki AA, Hamdi J, Thiga R, Sheikha A. Prevalence of antibody to hepatitis C virus in Saudi blood donors. Canadian Journal of Gastroenterology and Hepatology. 1995;9(3):141-3.
 * 40) Al-Wabel A, Al Knawy BA, Raziuddin S. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis. Clinical Immunology and Immunopathology. 1995 Mar 1;74(3):231-5.
 * 41) Malik GM, Abdalla RE, Al-Knawy BA, Abdalla SE. Lymphoma as a cause of false positive serology for visceral leishmaniasis (kala-azar) using the indirect haemagglutination (IHA) method. The Journal of Tropical Medicine and Hygiene. 1995 Aug;98(4):285-6.